CAP 002
Alternative Names: Adeno-associated virus (AAV) based gene therapy - Capsida Biotherapeutics; CAP-002Latest Information Update: 14 May 2024
At a glance
- Originator Capsida Biotherapeutics
- Class Antiepileptic drugs; Gene therapies
- Mechanism of Action Gene transference; Munc18 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Epilepsy
Highest Development Phases
- Preclinical Epilepsy
Most Recent Events
- 07 May 2024 Updated pharmacodynamic data from preclinical study in epilepsy released by Capsida Biotherapeutics
- 22 Apr 2024 Capsida Biotherapeutics plans a clinical trial for Epilepsy (IV) in the first half of 2025
- 22 Apr 2024 Pharmacodynamics data from preclinical studies in Epilepsy released by Capsida Biotherapeutics